Brief: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics

04/03/2024 12:04

March 4 (Reuters) - C4 Therapeutics Inc  CCCC.O :
    * C4 THERAPEUTICS ANNOUNCES STRATEGIC DISCOVERY RESEARCH
COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AGAINST
CRITICAL ONCOGENIC PROTEINS
    * C4 THERAPEUTICS INC: C4T TO RECEIVE A $16 MILLION UPFRONT
PAYMENT
    * C4 THERAPEUTICS INC: MERCK KGAA, DARMSTADT, GERMANY, TO
COVER
DISCOVERY RESEARCH COSTS UNDER COLLABORATION
    * C4 THERAPEUTICS INC: C4T ELIGIBLE FOR UP TO APPROXIMATELY
$740
MILLION IN DISCOVERY, DEVELOPMENT AND COMMERCIAL MILESTONE
PAYMENTS
    * C4 THERAPEUTICS: WILL UTILIZE PROPRIETARY TORPEDO PLATFORM
TO
DISCOVER DEGRADERS TARGETING PARTNERSHIP'S ONCOGENIC PROTEINS OF
INTEREST
    * C4 THERAPEUTICS: MERCK KGAA, DARMSTADT, GERMANY,
RESPONSIBLE FOR
CLINICAL DEVELOPMENT, COMMERCIALIZATION FOR DRUG CANDIDATES

Source text for Eikon:  ID:nGNX2FLzG0 
Further company coverage:  CCCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))